Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 3 | 2016 | 159 | 0.800 |
Why?
|
| Anus Neoplasms | 1 | 2018 | 24 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 994 | 0.530 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 13 | 0.520 |
Why?
|
| Embolism | 1 | 2015 | 20 | 0.520 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 107 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 322 | 0.500 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2014 | 5 | 0.490 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 55 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 633 | 0.460 |
Why?
|
| Pyrazoles | 1 | 2014 | 115 | 0.450 |
Why?
|
| Pyrimidines | 1 | 2014 | 194 | 0.440 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2006 | 188 | 0.430 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 466 | 0.420 |
Why?
|
| Biliary Tract Diseases | 1 | 2012 | 12 | 0.420 |
Why?
|
| Actinomycosis | 1 | 2012 | 10 | 0.420 |
Why?
|
| Salvage Therapy | 1 | 2013 | 139 | 0.420 |
Why?
|
| Bile Duct Neoplasms | 1 | 2012 | 29 | 0.410 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 182 | 0.410 |
Why?
|
| Prognosis | 6 | 2019 | 1959 | 0.380 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1041 | 0.380 |
Why?
|
| Benzenesulfonates | 2 | 2011 | 10 | 0.380 |
Why?
|
| Middle Aged | 12 | 2020 | 12234 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 193 | 0.360 |
Why?
|
| Stroke | 1 | 2015 | 482 | 0.360 |
Why?
|
| Pyridines | 2 | 2011 | 132 | 0.340 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 328 | 0.330 |
Why?
|
| Colorectal Neoplasms | 2 | 2003 | 238 | 0.330 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 3140 | 0.300 |
Why?
|
| Heparin | 1 | 2007 | 91 | 0.280 |
Why?
|
| Drug Industry | 1 | 2007 | 38 | 0.280 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 83 | 0.280 |
Why?
|
| Communication Barriers | 1 | 2007 | 33 | 0.280 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2006 | 3 | 0.280 |
Why?
|
| raf Kinases | 1 | 2006 | 4 | 0.280 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 82 | 0.280 |
Why?
|
| Aged | 9 | 2020 | 9427 | 0.260 |
Why?
|
| Anticoagulants | 1 | 2007 | 255 | 0.240 |
Why?
|
| Thrombosis | 1 | 2007 | 249 | 0.240 |
Why?
|
| Skin | 1 | 2007 | 415 | 0.240 |
Why?
|
| Adult | 9 | 2020 | 13384 | 0.240 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 387 | 0.230 |
Why?
|
| Female | 11 | 2020 | 26668 | 0.230 |
Why?
|
| Survival Rate | 2 | 2018 | 902 | 0.220 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 394 | 0.220 |
Why?
|
| Humans | 16 | 2020 | 50251 | 0.220 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2180 | 0.210 |
Why?
|
| Camptothecin | 1 | 2002 | 16 | 0.200 |
Why?
|
| Male | 10 | 2020 | 25483 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 71 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 609 | 0.190 |
Why?
|
| Oximes | 1 | 2020 | 13 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 484 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2020 | 18 | 0.180 |
Why?
|
| Pyridones | 1 | 2020 | 35 | 0.180 |
Why?
|
| Thalidomide | 1 | 2002 | 377 | 0.170 |
Why?
|
| Imidazoles | 1 | 2020 | 128 | 0.170 |
Why?
|
| Cholangiocarcinoma | 2 | 2011 | 26 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 207 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2020 | 666 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1186 | 0.150 |
Why?
|
| Melanoma | 1 | 2020 | 290 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 747 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 641 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 957 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 461 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 496 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2015 | 57 | 0.120 |
Why?
|
| Adenine | 1 | 2014 | 32 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 47 | 0.120 |
Why?
|
| Genes, myc | 1 | 2015 | 41 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2018 | 6172 | 0.120 |
Why?
|
| United States | 3 | 2019 | 4887 | 0.120 |
Why?
|
| Piperidines | 1 | 2014 | 97 | 0.120 |
Why?
|
| Registries | 3 | 2007 | 513 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2015 | 270 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5186 | 0.110 |
Why?
|
| Quinazolines | 1 | 2013 | 33 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 186 | 0.110 |
Why?
|
| Actinomyces | 1 | 2012 | 9 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 828 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 74 | 0.100 |
Why?
|
| Comorbidity | 2 | 2019 | 606 | 0.100 |
Why?
|
| Gallbladder Neoplasms | 1 | 2011 | 7 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 225 | 0.100 |
Why?
|
| Phenylurea Compounds | 2 | 2011 | 15 | 0.090 |
Why?
|
| Niacinamide | 2 | 2011 | 22 | 0.090 |
Why?
|
| Incidence | 2 | 2019 | 986 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 1250 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 14 | 0.070 |
Why?
|
| Necrosis | 1 | 2007 | 178 | 0.070 |
Why?
|
| Causality | 1 | 2007 | 44 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2007 | 77 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 156 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 167 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 163 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 1169 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 236 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 92 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 745 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2007 | 95 | 0.070 |
Why?
|
| Syndrome | 1 | 2006 | 239 | 0.070 |
Why?
|
| Patient Selection | 1 | 2007 | 252 | 0.060 |
Why?
|
| Publication Bias | 1 | 2005 | 11 | 0.060 |
Why?
|
| Editorial Policies | 1 | 2005 | 11 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2005 | 57 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1377 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2007 | 1257 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2020 | 19 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 580 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 79 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2020 | 106 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 374 | 0.040 |
Why?
|
| Trisaccharides | 1 | 2019 | 1 | 0.040 |
Why?
|
| Premedication | 1 | 2019 | 21 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 435 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 1542 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 214 | 0.040 |
Why?
|
| Antibodies | 1 | 2019 | 155 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2003 | 408 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 176 | 0.040 |
Why?
|
| Arkansas | 1 | 2003 | 1962 | 0.040 |
Why?
|
| Adolescent | 1 | 2007 | 6402 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 259 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 486 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 4002 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 454 | 0.020 |
Why?
|